Header widget area left
Header widget area right
Viewing posts categorised under: Uncategorized

European Funding for Novel Technology

Posted by InformBioscience in News, Uncategorized | 0 comments

Irish SME wins EU funding for novel test to detect preeclampsia ec.europa.eu

Diarmuid Cahalane Listed Founding Member of Biobank Association

Posted by InformBioscience in News, Uncategorized | 0 comments

www.molecularmedicineireland.ie

Inform Bioscience to attend BioTrinity European conference in London

Posted by InformBioscience in News, Uncategorized | 0 comments

Inform Bioscience will attend the upcoming BioTrinity Partnering and Investment Conference in London May 11-13 2015 The company will also participate in the one to one meetings and is happy to meet with potential partners at this event. For more information visit the Biotrinity website at www.biotrinity.com   informlogoLogoWithStraplineV2horizon2020-1

Parent company Metabolomic Diagnostics secures $1million in second round funding

Posted by InformBioscience in Uncategorized | 0 comments

Metabolomic Diagnostics secures €750k in second round funding 05.02.2015 Diagnostics60-SMILE Co Cork based company Metabolomic Diagnostics has secured an additional €750,000 in venture funding bringing the total investment in the company in the past year to €1.5m. The SOSventures Ireland Fund, as well as the AIB Seed Capital Fund and Enterprise Ireland, have invested in the company, which has developed novel, predictive diagnostic tests for the early detection of pre-eclampsia during pregnancy. Based in the Hoffmann Business Park, Little Island, Co Cork, Metabolomic Diagnostics currently employs seven people. “The second round of funding shows the sustained confidence in our pre-eclampsia tests, which are being developed at our site in Little Island in Cork,” said Charles Garvey, CEO Metabolomic Diagnostics. “With almost 80,000 deaths each year globally as a result of pre-eclampsia, this technology has the potential to save lives and revolutionise pre-natal care.” Pre-eclampsia is characterised by rapidly increasing blood pressure and elevated protein in urine and once it escalates, the only treatment option is the delivery of the baby, often prematurely. The result of significant research into metabolomic biomarkers, the diagnostic blood test will be able to detect the risk of pre-eclampsia early on in the pregnancy and ultimately save the lives of women and their babies through personalised medical interventions. metaboll1 Frank Walsh, partner, Enterprise Equity (manager AIB Seed Capital Fund); Katy Hyland, regulatory scientist, Metabolomic Diagnostic and Charles Garvey, CEO Metabolomic Diagnostics

Inform Bioscience attends Bio Europe in Frankfurt Nov 3rd-5th

Posted by InformBioscience in Uncategorized | 0 comments

    beu14_banner http://www.ebdgroup.com/bioeurope/index.php

December 2018
M T W T F S S
« Apr    
 12
3456789
10111213141516
17181920212223
24252627282930
31